Every third tablet consumed globally is manufactured in India; work on for first indigenous HPV vaccine

Did you know that every third tablet consumed globally is manufactured in India? Yes, you heard that right. India’s pharma sector has achieved tremendous success in the past several years.

Here are the key achievements:

India has emerged as a global hub for affordable, high-quality medicines, ranking 3rd in pharmaceutical production by volume and 14th by value.

India developed the world’s first DNA vaccine for COVID-19, showcasing innovation in global health.

Produces 65% of the world’s vaccines, significantly benefiting low- and middle-income countries.

The "Make in India" initiative is reducing dependency on imported Active Pharmaceutical Ingredients (APIs) through strengthened domestic manufacturing.

The Pharma industry has transitioned from a generic-focused model to developing biopharmaceuticals and biosimilars.

India is working on the first indigenous HPV vaccine to prevent cervical cancer in adolescent girls.

Key Takeaways

India's bioeconomy has grown from $10 billion in 2014 to $165.7 billion in 2024, with a target of $300 billion by 2030.

The sector contributes 4.25% to GDP with a compound annual growth rate (CAGR) of 17.9% over the past four years.

This exceptional expansion reflects the nation’s focused efforts to position biotechnology as a cornerstone of sustainable economic growth and innovation. Contributing 4.25% to the national GDP, the sector has demonstrated a robust compound annual growth rate (CAGR) of 17.9% over the past four years, reinforcing India’s emergence as a rising global force in biotechnology.

The bioeconomy is the use of renewable biological resources to produce food, energy and industrial goods, which supports sustainability and economic growth.